Immunic Inc [IMUX] stock is trading at $1.25, up 6.84%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IMUX shares have gain 10.62% over the last week, with a monthly amount glided 4.17%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright started tracking the stock with Buy rating on November 25, 2024, and set its price target to $10. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $6 on August 27, 2024. SVB Leerink downgraded its rating to a Mkt Perform but $5 remained the price target by the analyst firm on October 21, 2022. In a note dated April 15, 2021, Aegis Capital initiated an Buy rating and provided a target price of $55 on this stock.
Immunic Inc [IMUX] stock has fluctuated between $0.92 and $2.11 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Immunic Inc [NASDAQ: IMUX] shares were valued at $1.25 at the most recent close of the market. An investor can expect a potential return of 300.0% based on the average IMUX price forecast.
Analyzing the IMUX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.5, Equity is -1.78 and Total Capital is -2.31. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1767 points at the first support level, and at 1.1033 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3367, and for the 2nd resistance point, it is at 1.4233.
Ratios To Look Out For
For context, Immunic Inc’s Current Ratio is 2.71. Further, the Quick Ratio stands at 2.71, while the Cash Ratio is 2.53.
Transactions by insiders
Recent insider trading involved Rudick Richard Alan, Director, that happened on Nov 12 ’24 when 87300.0 shares were purchased.
